People with chronic lung conditions that affect their breathing, such as asthma or chronic obstructive pulmonary disorder, or ...

Medscape Medical News, August 08, 2023 Study Questions Use of Branded Inhalers for COPD Researchers said their analysis found that a generic product approved in 2019 was equally effective as the ...

In the USA, 14.8 million people were diagnosed with chronic obstructive pulmonary disease (COPD) in 2010 and nearly as many are expected to go undiagnosed. Indirect costs of COPD were projected to ...

Indian pharmaceutical firm Cipla is sharpening its aim to become a leader in respiratory medications in the United States ... announced that it filed two generic respiratory drug applications ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

“In the United States, while 93% of Teva’s inhaler medicines are generic products with access at lower prices – particularly for insured patients – there still remain uninsured patients ...

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...